ASH 2024: Johnson & Johnson showcases innovations in multiple myeloma, B-cell malignancies, and autoimmune disorders
Johnson & Johnson announced more than 90 abstracts featuring data from the Company’s differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH)… read more.